Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses how to best approach relapse in acute myeloid leukemia (AML) in the era of targeted therapies. Dr Stein explains that at the time of relapse, patients should be tested for new mutations and be treated with a targeted agent when possible. In addition, Dr Stein mentions the growing role of immunotherapies in this setting. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.